2. PI3K/Akt/mTOR Epigenetics NF-κB MAPK/ERK Pathway
  3. Akt AMPK NF-κB p38 MAPK
  4. Indoprofen

Indoprofen  (Synonyms: (±)-Indoprofe)

Cat. No.: HY-B1104 Purity: 99.52%
SDS
COA
Handling Instructions Technical Support

Indoprofen ((±)-Indoprofe) activates AKT-AMPK signaling pathway, inhibits NF-κB/MAPK signaling pathway. Indoprofen exhibits anti-inflammatory and immunomodulatory activities. Indoprofen is orally active.

For research use only. We do not sell to patients.

Indoprofen Chemical Structure

Indoprofen Chemical Structure

CAS No. : 31842-01-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Indoprofen:

Indoprofen Related Antibodies

Top Publications Citing Use of Products

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All AMPK Isoform Specific Products:

View All Isoforms
NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Indoprofen ((±)-Indoprofe) activates AKT-AMPK signaling pathway, inhibits NF-κB/MAPK signaling pathway. Indoprofen exhibits anti-inflammatory and immunomodulatory activities. Indoprofen is orally active[1][2].

In Vitro

Indoprofen (1-200 μM, 48 h) promotes PGC-1α expression, induces the formation of Myh-positive myotubes, inhibits Dexamethasone (HY-14648)-induced myotube atrophy and restores Myh protein level[1].
Indoprofen (1-200 μM, 48 h) enhances the oxidative metabolism capacity of muscles by regulating the expression of oxidative metabolism related proteins[1].
Indoprofen (7.5-20 μM, 12 h) reduces rhHMGB1-induced production of inflammatory factor (such as TNF-α, IL-1β, IL-6 and PGE2), and reduces the expression of TLR2, TLR4 and RAGE on the THP-1 cell surface[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Indoprofen Related Antibodies

Western Blot Analysis[1]

Cell Line: C2C12
Concentration: 1-200 μM
Incubation Time: 48 h
Result: Upregulated the expression of total-OXPHOS (oxidative phosphorylation complex) and myoglobin.

Real Time qPCR[2]

Cell Line: THP-1
Concentration: 7.5-20 μM
Incubation Time: 24 h
Result: Reduced the expression of RAGE.
In Vivo

Indoprofen (2 mg/kg, po, once daily for 2-12 weeks) improves muscle mass and strength in mice, improves the muscle function in aged mice. Indoprofen prevents the reduction of myotube formation, and enhances fatigue resistance against Dexamethasone (HY-14648)-induced disuse muscle atrophy[1].
Indoprofen (20-40 mg/kg, ip, single dose) reduces the inflammatory response and tissue damage caused by sepsis and improves the survival rate of septic mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mouse model[1]
Dosage: 2 mg/kg
Administration: po, once daily for 2-12 weeks
Result: Improved muscle mass and strength in young and old mice.
Improved muscle function in aged mice, including running distance, grip strength, and isometric force.
Prevented muscle fiber thinning, improved muscle strength in dexamethasone-stimulated mice.
Animal Model: Cecal ligation and puncture (CLP)-induced sepsis in mouse models[2]
Dosage: 20-40 mg/kg
Administration: ip, single dose
Result: Alleviated pulmonary edema. Reduced pathological damage in the lung, heart, liver, kidney and colon. Improved the survival rate of septic mice
Molecular Weight

281.31

Formula

C17H15NO3
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(O)C(C)C1=CC=C(N(CC2=C3C=CC=C2)C3=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (355.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.5548 mL 17.7740 mL 35.5480 mL
5 mM 0.7110 mL 3.5548 mL 7.1096 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.08 mg/mL (7.39 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.08 mg/mL (7.39 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 25 mg/mL (88.87 mM); Suspended solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  0.5% CMC/saline water

    Solubility: 50 mg/mL (177.74 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.52%

SDS (643 KB)

COA (247 KB) LCMS (112 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.5548 mL 17.7740 mL 35.5480 mL 88.8699 mL
5 mM 0.7110 mL 3.5548 mL 7.1096 mL 17.7740 mL
10 mM 0.3555 mL 1.7774 mL 3.5548 mL 8.8870 mL
15 mM 0.2370 mL 1.1849 mL 2.3699 mL 5.9247 mL
20 mM 0.1777 mL 0.8887 mL 1.7774 mL 4.4435 mL
25 mM 0.1422 mL 0.7110 mL 1.4219 mL 3.5548 mL
30 mM 0.1185 mL 0.5925 mL 1.1849 mL 2.9623 mL
40 mM 0.0889 mL 0.4443 mL 0.8887 mL 2.2217 mL
50 mM 0.0711 mL 0.3555 mL 0.7110 mL 1.7774 mL
60 mM 0.0592 mL 0.2962 mL 0.5925 mL 1.4812 mL
80 mM 0.0444 mL 0.2222 mL 0.4443 mL 1.1109 mL
100 mM 0.0355 mL 0.1777 mL 0.3555 mL 0.8887 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Indoprofen Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Indoprofen31842-01-0(±)-IndoprofeAktAMPKNF-κBp38 MAPKPKBProtein kinase BAMP-activated protein kinaseNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Indoprofen
Cat. No.:
HY-B1104
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (643 KB) Français - FR (643 KB) Deutsch - DE (643 KB) Norwegian - NO (643 KB) Español - ES (643 KB) Swedish - SV (643 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.